- Page 1 and 2:
METHODS IN MOLECULAR BIOLOGY 360 T
- Page 3 and 4:
M E T H O D S I N M O L E C U L A R
- Page 5 and 6:
© 2007 Humana Press Inc. 999 River
- Page 7 and 8:
vi Preface get. Approaches to targe
- Page 9 and 10:
viii Contents 10 Transgenic Animal
- Page 11 and 12:
x Contributors SAHOHIME MATSUMOTO
- Page 13 and 14:
xii Contents of Volume 2 12 Validat
- Page 15 and 16:
2 Sioud disease pathogenesis and pe
- Page 17 and 18:
4 Sioud A more fruitful approach fo
- Page 19 and 20:
6 Sioud both transient and permanen
- Page 21 and 22:
8 Sioud serum biomarkers. This syne
- Page 23 and 24:
10 Sioud Fig. 2. Schematic of targe
- Page 25 and 26:
12 Sioud 13. Magin, T. M. (1998) Le
- Page 28 and 29:
Harnessing the Human Genome 15 The
- Page 30 and 31:
Harnessing the Human Genome 17 Fig.
- Page 32 and 33:
Harnessing the Human Genome 19 Fig.
- Page 34 and 35:
Harnessing the Human Genome 21 Fig.
- Page 36 and 37:
Harnessing the Human Genome 23 The
- Page 38 and 39:
Harnessing the Human Genome 25 Fig.
- Page 40 and 41:
Harnessing the Human Genome 27 repr
- Page 42 and 43:
Harnessing the Human Genome 29 14.
- Page 44:
Harnessing the Human Genome 31 45.
- Page 47 and 48:
34 Imoto et al. (4,5), and Bayesian
- Page 49 and 50:
36 Imoto et al. 2. Materials Two ty
- Page 51 and 52:
38 Imoto et al. Fig. 3. Graphical v
- Page 53 and 54:
40 Imoto et al. Fig. 5. Result of t
- Page 55 and 56:
42 Imoto et al. p(D |G) = ∫ p(D,
- Page 57 and 58:
44 Imoto et al. β k (k = 1,…,q j
- Page 59 and 60:
46 Imoto et al. Fig. 7. Partial res
- Page 61 and 62:
48 Imoto et al. Fig. 8. Strategy to
- Page 63 and 64:
50 Imoto et al. Fig. 9. (continued)
- Page 65 and 66:
52 Imoto et al. Table 3 List of Roo
- Page 67 and 68:
54 Imoto et al. 5. De Hoon, M. J. L
- Page 69 and 70:
56 Imoto et al. 39. Kamimura, T., S
- Page 71 and 72:
58 Beaty et al. cytotoxic drugs and
- Page 73 and 74:
60 Beaty et al. Fig. 1. Principles
- Page 75 and 76:
62 Beaty et al. oligonucleotide mic
- Page 77 and 78:
64 Beaty et al. 3. The 12% polyacry
- Page 79 and 80:
66 Beaty et al. 2.3.3. Protein Stai
- Page 81 and 82:
68 Beaty et al. 3.1.3. Labeling of
- Page 83 and 84:
70 Beaty et al. 1 µL of the anneal
- Page 85 and 86:
72 Beaty et al. 4. Phenol:cholorfor
- Page 87 and 88:
74 Beaty et al. 19. Wash twice with
- Page 89 and 90:
76 Beaty et al. The Following Volum
- Page 91 and 92:
78 Beaty et al. using a protein ass
- Page 93 and 94:
80 Beaty et al. 6. Shake the gel fo
- Page 95 and 96:
82 Beaty et al. Fig. 2. Preparation
- Page 97 and 98:
84 Beaty et al. search in. A widely
- Page 99 and 100:
86 Beaty et al. 3. Kern, S. E., Hru
- Page 101 and 102:
88 Beaty et al. 34. Peters, D. G.,
- Page 104 and 105:
5 Molecular Classification of Breas
- Page 106 and 107:
Molecular Profiling of Breast Cance
- Page 108 and 109:
Molecular Profiling of Breast Cance
- Page 110 and 111:
Fig. 2. (Continued) the right ident
- Page 112 and 113:
Molecular Profiling of Breast Cance
- Page 114 and 115:
Molecular Profiling of Breast Cance
- Page 116 and 117: Molecular Profiling of Breast Cance
- Page 118 and 119: Molecular Profiling of Breast Cance
- Page 120 and 121: Molecular Profiling of Breast Cance
- Page 122 and 123: Molecular Profiling of Breast Cance
- Page 124 and 125: Molecular Profiling of Breast Cance
- Page 126 and 127: Molecular Profiling of Breast Cance
- Page 128 and 129: 6 Discovery of Differentially Expre
- Page 130 and 131: Gene Target Discovery 117 In the fi
- Page 132 and 133: Gene Target Discovery 119 sequences
- Page 134 and 135: Gene Target Discovery 121 There is
- Page 136 and 137: Gene Target Discovery 123 digestion
- Page 138 and 139: Gene Target Discovery 125 Fig. 1. P
- Page 140 and 141: Gene Target Discovery 127 5. Sargen
- Page 142: Gene Target Discovery 129 41. Berry
- Page 145 and 146: 132 Matsumoto, Miyagishi, and Taira
- Page 147 and 148: 134 Matsumoto, Miyagishi, and Taira
- Page 149 and 150: 136 Matsumoto, Miyagishi, and Taira
- Page 151 and 152: 138 Matsumoto, Miyagishi, and Taira
- Page 153 and 154: 140 Matsumoto, Miyagishi, and Taira
- Page 155 and 156: 142 Matsumoto, Miyagishi, and Taira
- Page 157 and 158: 144 Fig. 1. The ribozyme-expression
- Page 159 and 160: 146 Sano and Taira 5. 10X L (low-sa
- Page 161 and 162: 148 Sano and Taira ribozymes may cl
- Page 163 and 164: 150 Fig. 3. A system for the identi
- Page 165: 152 Sano and Taira 4. Notes 1. We r
- Page 169 and 170: 156 Erfle and Pepperkok 2. Material
- Page 171 and 172: 158 Erfle and Pepperkok cells away
- Page 173 and 174: 160 Erfle and Pepperkok 5. The stai
- Page 176 and 177: 10 Transgenic Animal Models in Biom
- Page 178 and 179: Transgenic Models 165 giant mice ex
- Page 180 and 181: Transgenic Models 167 2.1.3. Use of
- Page 182 and 183: Transgenic Models 169 a recombinant
- Page 184 and 185: Transgenic Models 171 Fig. 3. Diffe
- Page 186 and 187: Transgenic Models 173 FRT sites are
- Page 188 and 189: Transgenic Models 175 Fig. 4. Diffe
- Page 190 and 191: Transgenic Models 177 models, the b
- Page 192 and 193: Transgenic Models 179 Fig. 6. Vecto
- Page 194 and 195: Transgenic Models 181 vectors can d
- Page 196 and 197: Transgenic Models 183 then used to
- Page 198 and 199: Transgenic Models 185 be fixed and
- Page 200 and 201: Transgenic Models 187 period of inc
- Page 202 and 203: Transgenic Models 189 (142). Genes
- Page 204 and 205: Transgenic Models 191 from differen
- Page 206 and 207: Transgenic Models 193 Acknowledgmen
- Page 208 and 209: Transgenic Models 195 34. Thermes,
- Page 210 and 211: Transgenic Models 197 68. Gupta, S.
- Page 212 and 213: Transgenic Models 199 105. Weber, W
- Page 214 and 215: Transgenic Models 201 138. Ranger,
- Page 216 and 217:
11 Keratin Transgenic and Knockout
- Page 218 and 219:
Keratin Transgenics and Knockouts 2
- Page 220 and 221:
Keratin Transgenics and Knockouts 2
- Page 222 and 223:
Keratin Transgenics and Knockouts 2
- Page 224 and 225:
211 K17 K17 Hair follicles, Alopeci
- Page 226 and 227:
213 K6a K6a Hair follicles; Lysis o
- Page 228 and 229:
Keratin Transgenics and Knockouts 2
- Page 230 and 231:
Keratin Transgenics and Knockouts 2
- Page 232 and 233:
Keratin Transgenics and Knockouts 2
- Page 234 and 235:
Keratin Transgenics and Knockouts 2
- Page 236 and 237:
Keratin Transgenics and Knockouts 2
- Page 238 and 239:
Keratin Transgenics and Knockouts 2
- Page 240 and 241:
Keratin Transgenics and Knockouts 2
- Page 242 and 243:
Keratin Transgenics and Knockouts 2
- Page 244 and 245:
Keratin Transgenics and Knockouts 2
- Page 246 and 247:
Keratin Transgenics and Knockouts 2
- Page 248 and 249:
Keratin Transgenics and Knockouts 2
- Page 250 and 251:
Keratin Transgenics and Knockouts 2
- Page 252 and 253:
Keratin Transgenics and Knockouts 2
- Page 254 and 255:
Keratin Transgenics and Knockouts 2
- Page 256 and 257:
Keratin Transgenics and Knockouts 2
- Page 258 and 259:
Keratin Transgenics and Knockouts 2
- Page 260 and 261:
Keratin Transgenics and Knockouts 2
- Page 262 and 263:
Keratin Transgenics and Knockouts 2
- Page 264:
Keratin Transgenics and Knockouts 2
- Page 267:
254 Skovseth, Küchler, and Haralds
- Page 270 and 271:
In Vivo Assay of Human Angiogenesis
- Page 272 and 273:
In Vivo Assay of Human Angiogenesis
- Page 274 and 275:
In Vivo Assay of Human Angiogenesis
- Page 276 and 277:
In Vivo Assay of Human Angiogenesis
- Page 278 and 279:
In Vivo Assay of Human Angiogenesis
- Page 280 and 281:
In Vivo Assay of Human Angiogenesis
- Page 282 and 283:
13 A Murine Model for Studying Hema
- Page 284 and 285:
Heart Failure and Immunity 271 We h
- Page 286 and 287:
Heart Failure and Immunity 273 3.1.
- Page 288:
Heart Failure and Immunity 275 6. W
- Page 291 and 292:
278 Sioud gene products have been d
- Page 293 and 294:
280 Sioud Fig. 1. Schematic of hema
- Page 295 and 296:
282
- Page 297 and 298:
284
- Page 299 and 300:
286 Sioud selection), whereas thymo
- Page 301 and 302:
288 Sioud Fig. 5. Affinity maturati
- Page 303 and 304:
290 Sioud Fig. 6. A second signal i
- Page 305 and 306:
292 Sioud Fig. 7. Bridging between
- Page 307 and 308:
294 Sioud Fig. 8. Schematic of clas
- Page 309 and 310:
296 Sioud Fig. 10. Critical molecul
- Page 311 and 312:
298 Sioud In contrast to the expres
- Page 313 and 314:
300 Sioud tumor infiltrating lympho
- Page 315 and 316:
302 Sioud (see Chapter 15, Volume 1
- Page 317 and 318:
304 Sioud display if the foreign pr
- Page 319 and 320:
306 Sioud Fig. 13. Immunoscreening
- Page 321 and 322:
308 Sioud molecular techniques have
- Page 323 and 324:
310 Sioud Although much of the init
- Page 325 and 326:
312 Sioud Because of their importan
- Page 327 and 328:
314 Sioud 22. He, X., Janeway, C. A
- Page 329 and 330:
316 Sioud 59. Sahin, U., Tureci, O.
- Page 331 and 332:
318 Sioud 91. Golgher, D., Jones, E
- Page 333 and 334:
320 Jäger Furthermore, this immune
- Page 335 and 336:
322 Jäger Antigens that are tumor-
- Page 337 and 338:
324 Jäger 2. Nakano, O., Sato, M.,
- Page 339 and 340:
326 Jäger 31. Chen, Y. T., Gure, A
- Page 341 and 342:
328 Le Naour dependent on CD8+ cyto
- Page 343 and 344:
330 Le Naour Fig. 1. To illustrate
- Page 345 and 346:
332 Le Naour heterogeneity of HCC,
- Page 347 and 348:
334 Le Naour 15. Le Naour, F., Mise
- Page 349 and 350:
336 Cekaite, Hovig, and Sioud Yeast
- Page 351 and 352:
338 Cekaite, Hovig, and Sioud diffe
- Page 353 and 354:
340
- Page 355 and 356:
342 Cekaite, Hovig, and Sioud nonra
- Page 357 and 358:
344 Cekaite, Hovig, and Sioud 3. Ue
- Page 359 and 360:
346 Cekaite, Hovig, and Sioud 32. T
- Page 361 and 362:
348 Cekaite, Hovig, and Sioud 65. L
- Page 363 and 364:
350 Index Centroblast, 289 Centrocy
- Page 365 and 366:
352 Index L Labeling mRNA, 62 Large
- Page 367:
354 Index Tetraploid embryos, 239 g